Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1BYDUREON[1] Exenatide (BYDUREON BCise)[1] Exenatide (BYDUREON) 💬 [1] GLP1R 💬 [3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬[2] 6, 17 💬
2Bydureon 2 mg powder and solvent for prolonged-release suspension[2] Exenatide (BYDUREON BCise),
Manganese citrate		[1] Exenatide (BYDUREON) 💬 [1] GLP1R 💬 [3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬[1] 6 💬
3Exenatide
(BYDUREON)		[1] Exenatide (BYDUREON BCise)[1] Exenatide (BYDUREON) 💬 [1] GLP1R 💬 [3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬[6] 6, 17, 72, 78, 193, 233 💬
4Exenatide 10 micrograms
(BYDUREON)		[1] Exenatide (BYDUREON BCise)[1] Exenatide (BYDUREON) 💬 [1] GLP1R 💬 [3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬[1] 6 💬
5Exenatide 5 micrograms
(BYDUREON)		[1] Exenatide (BYDUREON BCise)[1] Exenatide (BYDUREON) 💬 [1] GLP1R 💬 [3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬[1] 6 💬
6Exenatide extended release 2mg (Bydureon)[1] Exenatide (BYDUREON BCise)[1] Exenatide (BYDUREON) 💬 [1] GLP1R 💬 [3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬[1] 6 💬
7Exenatide Pen Injector [Bydureon][1] Exenatide (BYDUREON BCise)[1] Exenatide (BYDUREON) 💬 [1] GLP1R 💬 [3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬[1] 17 💬
8Experimental: GLP1-RA (exenatide) administration
(BYDUREON)		[1] Exenatide (BYDUREON BCise)[1] Exenatide (BYDUREON) 💬 [1] GLP1R 💬 [3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬[2] 72, 78 💬